文献速递主动脉疾病外周动脉疾病

血管白塞病动脉表现的腔内治疗早期与中期结局

Early and Midterm Outcomes of Endovascular Treatment in Arterial Manifestations of Vascular Behcet Disease.
PubMed 文献 · Ann Vasc Surg · 2022-12-30

作者认为腔内治疗联合适当药物治疗似乎是治疗选择。

要点

  • 21例血管白塞病动脉病变患者腔内修复技术成功率为100%。
  • 随访期间3例(14.3%)需再干预,1例因入路部位假性动脉瘤行开放手术。

核心结论

  • 作者认为,年轻患者认识白塞病尤其血管受累可挽救生命;根据早期和中期成功结果及低发病率与死亡率,腔内治疗联合适当药物治疗似乎是治疗选择。

研究设计与样本

  • 单中心回顾性研究,纳入2016年1月至2022年1月在本院因血管白塞病行动脉腔内修复的21例患者(16男5女,中位年龄42岁,范围31至46岁)。
  • 随访计划为术后第1个月、第6个月及此后每6个月;对有症状患者安排影像学检查及额外干预。
  • 主要结局为手术成功和再干预需求;次要结局为并发症和全因死亡。

主要发现

  • 随访期间3例(14.3%)出现鞘管插入部位血肿,无早期死亡。

临床怎么用

  • 作者认为,年轻患者认识白塞病尤其血管受累可挽救生命。
  • 作者认为,根据早期和中期成功结果及低发病率与死亡率,腔内治疗联合适当药物治疗似乎是治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Behcet's disease (BD), originally described by Hulusi Behcet in 1937, is a chronic relapsing inflammatory process of an immunologic syndrome and the involvement of the vascular system is called Vasculo-Behcet disease (VBD). This is a retrospective study evaluating 21 patients diagnosed with VBD who underwent endovascular treatment. METHODS: This single-center study was conducted between January 2016 and January 2022. Early and mid-term endovascular outcomes of a total of 21 patients (16 males, 5 females with a median age of 42 years; range, 31 to 46 years), with a diagnosis of VBD, who underwent endovascular arterial repair in our hospital, were retrospectively analyzed. Follow-ups were scheduled for the first and sixth postoperative months and every 6 months thereafter. For symptomatic patients, imaging studies and additional interventions were planned. The primary outcomes were a procedural success and a requirement for reintervention. Secondary outcomes were complications and all causes of mortality. RESULTS: Twenty-one patients underwent endovascular repair. In this study, 1 balloon-expandable stent for brachial artery aneurysm (4,8%), 1 viabahn graft for femoral artery aneurysm (4,8%), 2 tube endograft for ruptured iliac artery aneurysm (9,5%), 1 tube endograft (Thoracic endovascular aortic repair [TEVAR]) insertion at the aortic bifurcation for infrarenal abdominal aortic occlusion (4,8%), 1 chimney-TEVAR for saccular arcus thoracic aortic aneurysm (TAA) (4,8%) and 7 TEVAR for saccular TAA (33,3%), 1 EVAR for an intact and symptomatic infrarenal abdominal aortic aneurysm (AAA) (4,8%), 1 EVAR (aorto-uniiliac) for ruptured iliac artery aneurysm (4,8%), and 6 EVAR for ruptured AAA (28,5%) were deployed. The technical success rate was 100% with a mean follow-up period of 50. 4 ± 10.7 months (8-66 months). The mean aneurysm diameter was 10,7 ± 53 mm. In the follow-up period, 3 patients presented with a hematoma at the insertion site of the sheath (14.3%). There were no early mortalities. Three patients required reintervention (14,3%); 1 of these underwent open surgical repair due to a pseudoaneurysm of the access site (4,8%). The Kaplan-Meier analysis revealed freedom from reintervention rate as 94,1 ± 5,7% at 1 year, 85,6 ± 9,7% at 3 years, and 68,4 ± 17,1% at 5 years. CONCLUSIONS: Awareness of the BD especially for vascular involvements in young ages is lifesaving. Endovascular therapy with proper medical treatment seems to be the treatment of choice according to the early and midterm successful results with low morbidity and mortality.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. İscan HZ, Yigit G, Cetinkaya F, et al. Early and Midterm Outcomes of Endovascular Treatment in Arterial Manifestations of Vascular Behcet Disease. Ann Vasc Surg. 2022. PMID: 36587791. doi:10.1016/j.avsg.2022.12.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。